A detailed history of Advantage Alpha Capital Partners LP transactions in Veracyte, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 25,066 shares of VCYT stock, worth $1.03 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
25,066
Previous 45,729 45.19%
Holding current value
$1.03 Million
Previous $990,000 13.94%
% of portfolio
0.2%
Previous 0.22%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$21.0 - $35.25 $433,923 - $728,370
-20,663 Reduced 45.19%
25,066 $852,000
Q2 2024

Aug 13, 2024

SELL
$18.86 - $23.55 $90,622 - $113,157
-4,805 Reduced 9.51%
45,729 $990,000
Q1 2024

May 13, 2024

BUY
$21.0 - $29.1 $92,589 - $128,301
4,409 Added 9.56%
50,534 $1.12 Million
Q4 2023

Feb 13, 2024

BUY
$19.72 - $28.68 $909,585 - $1.32 Million
46,125 New
46,125 $1.27 Million

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.94B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Advantage Alpha Capital Partners LP Portfolio

Follow Advantage Alpha Capital Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advantage Alpha Capital Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Advantage Alpha Capital Partners LP with notifications on news.